The Phase 2 trial protocol specified that missed doses should not be doubled on the next injection day
Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, Plebani A, Kumararatne DS, Bonnet D, Tournilhac O, Tchernia G, Steiniger B, Staudt LM, Casanova JL, Reynaud CA, Weill JC: Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire
Current approaches include: Continuous Use Approach: Based on clinical trials that used continuous daily administration for 12-24 weeks without scheduled breaks
(4) Macro-B12 becomes a reasonable consideration when a value is very high, persists over time, comes with no B12 exposure, sits alongside an unrevealing workup, or disagrees with functional markers